NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company Nov 23, 2022 08:03AM
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Nov 23, 2022 08:00AM